Biomerica Management
Management criteria checks 3/4
Biomerica's CEO is Zack Irani, appointed in Apr 1997, has a tenure of 27.58 years. total yearly compensation is $360.10K, comprised of 41.7% salary and 58.3% bonuses, including company stock and options. directly owns 6.07% of the company’s shares, worth $327.60K. The average tenure of the management team and the board of directors is 3.9 years and 7.5 years respectively.
Key information
Zack Irani
Chief executive officer
US$360.1k
Total compensation
| CEO salary percentage | 41.7% |
| CEO tenure | 27.6yrs |
| CEO ownership | 6.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Recent updates
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?
Dec 20
Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation
Aug 31We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Mar 04Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Sep 29Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Sep 09Biomerica reports FY results
Aug 29Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device
Jul 14Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Dec 03Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans
Dec 02Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Sep 15Biomerica (BMRA) Investor Presentation - Slideshow
Jun 14Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Jun 13Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook
Apr 04Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?
Mar 08Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Feb 10The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders
Jan 15
Biomerica soars as its COVID-19 antigen test wins European nod
Jan 12When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?
Dec 20Biomerica clinical trial for IBS nears enrollment completion
Dec 09How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | -US$6m |
| May 31 2024 | US$360k | US$150k | -US$6m |
| Feb 29 2024 | n/a | n/a | -US$6m |
| Nov 30 2023 | n/a | n/a | -US$6m |
| Aug 31 2023 | n/a | n/a | -US$6m |
| May 31 2023 | US$141k | US$141k | -US$7m |
| Feb 28 2023 | n/a | n/a | -US$7m |
| Nov 30 2022 | n/a | n/a | -US$6m |
| Aug 31 2022 | n/a | n/a | -US$5m |
| May 31 2022 | US$491k | US$135k | -US$5m |
| Feb 28 2022 | n/a | n/a | -US$4m |
| Nov 30 2021 | n/a | n/a | -US$7m |
| Aug 31 2021 | n/a | n/a | -US$7m |
| May 31 2021 | US$488k | US$137k | -US$7m |
| Feb 28 2021 | n/a | n/a | -US$6m |
| Nov 30 2020 | n/a | n/a | -US$5m |
| Aug 31 2020 | n/a | n/a | -US$4m |
| May 31 2020 | US$330k | US$137k | -US$2m |
| Feb 29 2020 | n/a | n/a | -US$3m |
| Nov 30 2019 | n/a | n/a | -US$2m |
| Aug 31 2019 | n/a | n/a | -US$2m |
| May 31 2019 | US$329k | US$137k | -US$2m |
| Feb 28 2019 | n/a | n/a | -US$2m |
| Nov 30 2018 | n/a | n/a | -US$2m |
| Aug 31 2018 | n/a | n/a | -US$2m |
| May 31 2018 | US$295k | US$137k | -US$1m |
Compensation vs Market: Zack's total compensation ($USD360.10K) is below average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Zack's compensation has increased whilst the company is unprofitable.
CEO
Zack Irani (58 yo)
27.6yrs
Tenure
US$360,103
Compensation
Mr. Zackary S. Irani, also known as Zack, has been Chief Executive Officer of Biomerica Inc. since April 29, 1997 and is its Director and served as its President. He was Chairman of the Board at Biomerica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 27.6yrs | US$360.10k | 6.07% $ 327.6k | |
| Executive Vice-Chairman of the Board & Corporate Secretary | 25.1yrs | US$243.98k | 0.47% $ 25.1k | |
| Principal Accounting Officer & CFO | 1.7yrs | US$385.64k | 0% $ 0 | |
| Director of Manufacturing & Technical Operations | no data | no data | no data |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Management: BMRA's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$360.10k | 6.07% $ 327.6k | |
| Executive Vice-Chairman of the Board & Corporate Secretary | 25.1yrs | US$243.98k | 0.47% $ 25.1k | |
| Chairman of Strategic Advisory Board | 8.3yrs | no data | no data | |
| Member of Strategic Advisory Board | 6.6yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 17.6yrs | US$137.71k | 0.42% $ 22.8k | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Independent Director | 1.9yrs | US$157.82k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$145.21k | 0.26% $ 14.1k | |
| Chairman of Colorectal Screening Scientific Advisory Board | 3yrs | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data |
7.5yrs
Average Tenure
66yo
Average Age
Experienced Board: BMRA's board of directors are considered experienced (7.5 years average tenure).